SHILPAMED · NSE
Shilpa Medicare Limited
₹1,021.1
+6.55% (+₹62.75)
Prev. close
₹958.35
Volume
17,66,385
Delivery %
34.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Shilpa Medicare Limited
Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers GLP-1; HpAPI; intermediates; peptides; payloads and linkers; biopolymers; microbial and mammalian products; fermentation; small molecules; monoclonal antibodies and recombinant technology; and tablets, capsules, injectables, oral dissolving films, and transdermal patches. Further, it engages in wind power generation activities. The company serves wholesalers, distributors, doctors, pharmacy chain NGOs, hospitals, government institutions, and companies. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Vishnukant Chaturbhuj Bhutada B. Pharm
Headquarters
Raichur
Employees
1,241
Website
vbshilpa.comExchange
View on NSE ↗Key stats
Market cap
₹19,790.93 Cr
P/E ratio (TTM)
66.5
Dividend yield
0.06%
EPS (TTM)
₹15.22
Beta (1Y · daily vs NIFTY 50)
0.93
Beta (5Y · monthly vs NIFTY 50)
0.58
Shares float
9.37 Cr
EPS · quarter ended Jun 2026
₹5.16
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹830.32 Cr | ₹1,145.52 Cr | ₹1,050.11 Cr | ₹1,151.60 Cr | ₹1,286.41 Cr | ₹1,538.87 Cr | |
| EBITDA | ₹313.86 Cr | ₹223.23 Cr | ₹113.47 Cr | ₹245.92 Cr | ₹310.86 Cr | ₹473.82 Cr |
| ₹184.39 Cr | — | ₹-32.53 Cr | ₹31.87 Cr | ₹78.30 Cr | ₹243.33 Cr | |
| Diluted EPS | ₹11.31 | ₹3.63 | ₹1.87 | ₹1.84 | ₹4.02 | ₹12.44 |
Net income has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹2,875.50 Cr | ₹2,902.38 Cr | ₹3,093.20 Cr | ₹3,310.71 Cr | ₹3,705.61 Cr | |
| — | ₹683.29 Cr | ₹797.89 Cr | ₹937.39 Cr | ₹587.76 Cr | ₹659.86 Cr | |
| Stockholders' equity | — | ₹1,822.19 Cr | ₹1,783.28 Cr | ₹1,808.69 Cr | ₹2,372.24 Cr | ₹2,591.20 Cr |
Total assets, Current assets, Inventory, Receivables (trade + unbilled), Trade receivables, Unbilled receivables (contract assets), Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹80.71 Cr | ₹105.13 Cr | ₹179.92 Cr | ₹135.34 Cr | ₹132.18 Cr | ₹342.18 Cr | |
| Investing cash flow | ₹-249.21 Cr | ₹-285.50 Cr | ₹-232.61 Cr | ₹-166.58 Cr | ₹-199.08 Cr | ₹-325.92 Cr |
| ₹-255.58 Cr | ₹82.86 Cr | ₹45.80 Cr | ₹46.78 Cr | ₹62.65 Cr | ₹13.62 Cr | |
| Capital expenditure | ₹-288.09 Cr | ₹-331.83 Cr | ₹-226.67 Cr | ₹-184.56 Cr | ₹-243.63 Cr | ₹-370.63 Cr |
| End cash position | — | ₹25.34 Cr | ₹18.83 Cr | ₹31.76 Cr | ₹28.57 Cr | ₹45.18 Cr |
End cash position has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Nov 21–Mar 24(11Q) | Apr 24–Jun 24(2Q) | Sep 24 | Dec 24–Sep 25(4Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|---|---|---|
| Promoter | 53.25% | 50.01% | 44.39% | 44.33% | 44.23% | 40.13% |
| Public | 46.75% | 49.99% | 55.61% | 55.67% | 55.77% | 59.87% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Shilpa Medicare Limited | ₹18,242.89 Cr | ₹928.05 | 64.7 | 7.04 | 9.4% | 0.25 | +19.7% | +12.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
10 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Shilpa Medicare AGM 2026: Voting Results and Dividend Declared
Shilpa Medicare Limited's 39th Annual General Meeting confirmed the passing of all five resolutions, including a final dividend of Rs 0.60 per share for FY26. Shareholders also approved the re-appointment of a director and commission payment to a non-executive director of a subsidiary. One resolution saw 11.20% of votes against it.
Shilpa Medicare authorised to commence insolvency resolution for subsidiary FTF Pharma
Shilpa Medicare's wholly-owned subsidiary, FTF Pharma, has entered the Corporate Insolvency Resolution Process (CIRP) following an NCLT order. The insolvency application was filed by Immacule Lifesciences over an alleged operational debt. Shilpa Medicare is evaluating the impact on FTF Pharma and its own financial standing.